FDA Drug · D-0010-2027

Ranolazine Extended-Release Tablets, 1000 mg, 60-count bottle, Rx Only, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807. NDC: 27241-126-02

Class II · Ongoing

Failed Dissolution Specifications: below specification

Affected lots / codes — check yours against thisLot: DJ25134, Exp 11/30/2028

Recalling firm: Ajanta Pharma USA Inc, Bridgewater, NJ
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: —
Distribution: Nationwide in the US.
Recall initiated: September 17, 2026
Classified: October 6, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0010-2027%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →